Early experience with Suboxone maintenance therapy in Hungary.

Area of Science:

• Pharmacology
• Addiction Medicine
• Clinical Psychology

Background:

• Suboxone, a combination of buprenorphine and naloxone, is utilized for opiate substitution therapy.
• Introduced in Hungary in November 2007, Suboxone is administered sublingually.
• It contains a partial mu-receptor agonist (buprenorphine) and an antagonist (naloxone) in a 4:1 ratio.

Purpose of the Study:

• To monitor and evaluate the effects of Suboxone treatment in opiate-dependent patients.
• Assess the tolerability and applicability of Suboxone in a real-world clinical setting.
• Identify critical factors influencing treatment adherence and success.

Main Methods:

• A 6-month prospective study involving 80 opiate-dependent patients across 6 outpatient centers in Hungary.
• Data collection occurred at baseline, 1 month, 3 months, and 6 months using a comprehensive battery of psychological and addiction severity assessments.
• Utilized instruments included the Addiction Severity Index, Hamilton Depression and Anxiety Scales, and various craving and well-being inventories.

Main Results:

• A significant dropout rate (22.5%) was observed during the first month, particularly within the first week (15%).
• However, 40% of patients completed the full 6-month treatment period.
• Positive psychological and behavioral changes were evident within the first month and remained stable throughout the study.

Conclusions:

• Suboxone is a well-tolerated and effective medication for opiate addiction substitution therapy.
• The initial phase of treatment (first 1-2 weeks) is critical, with high dropout rates.
• Effective patient information, especially regarding early withdrawal symptoms, is crucial for enhancing treatment retention.